Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia Cosman

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 11, 2022
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc AnalysesFelicia Cosman, Shuang Huang, Michele McDermott, et al.
Clinical Therapeutics|August 19, 2007
Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studiesFelicia Cosman, Joao L C Borges, Manuel Diaz Curiel
Advances in Therapy|November 11, 2021
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative ReviewDavid L Kendler, Felicia Cosman, Robert Kees Stad, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 1, 2023
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtendFelicia Cosman, Didier Hans, Enisa Shevroja, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 21, 2012
Double and quadruple tetracycline labeling of bone: impact of the label itselfRobert Lindsay, Hua Zhou, Felicia Cosman, et al.
Bone|March 20, 2012
Changes in vitamin D metabolites during teriparatide treatmentFelicia Cosman, Bess Dawson-Hughes, Xiaohai Wan, et al.
Bone|November 21, 2022
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosisAravinda Ganapathy, Jeri W Nieves, Tony M Keaveny, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 31, 2008
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronateFelicia Cosman, Jeri W Nieves, Marsha Zion, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 20, 2025
Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trialAlexander S Dash, Karen Hind, Didier Hans, et al.
The New England Journal of Medicine|August 12, 2005
Daily and cyclic parathyroid hormone in women receiving alendronateFelicia Cosman, Jeri Nieves, Marsha Zion, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 11, 2022
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc AnalysesFelicia Cosman, Shuang Huang, Michele McDermott, et al.
Clinical Therapeutics|August 19, 2007
Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studiesFelicia Cosman, Joao L C Borges, Manuel Diaz Curiel
Advances in Therapy|November 11, 2021
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative ReviewDavid L Kendler, Felicia Cosman, Robert Kees Stad, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 1, 2023
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtendFelicia Cosman, Didier Hans, Enisa Shevroja, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 21, 2012
Double and quadruple tetracycline labeling of bone: impact of the label itselfRobert Lindsay, Hua Zhou, Felicia Cosman, et al.
Bone|March 20, 2012
Changes in vitamin D metabolites during teriparatide treatmentFelicia Cosman, Bess Dawson-Hughes, Xiaohai Wan, et al.
Bone|November 21, 2022
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosisAravinda Ganapathy, Jeri W Nieves, Tony M Keaveny, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 31, 2008
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronateFelicia Cosman, Jeri W Nieves, Marsha Zion, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 20, 2025
Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trialAlexander S Dash, Karen Hind, Didier Hans, et al.
The New England Journal of Medicine|August 12, 2005
Daily and cyclic parathyroid hormone in women receiving alendronateFelicia Cosman, Jeri Nieves, Marsha Zion, et al.
Pageof 12